Market research
PHPN.F Galectin Therapeutics, Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 311M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.38
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 311M
- P/E ratio
- Not available
- Analyst target
- 14
- Dividend yield
- Not available
- Beta
- 0.38
About
About Galectin Therapeutics, Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Research context
Galectin Therapeutics, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the PHPN.F discussion.
5 years, 7 months ago
Galectin Therapeutics Inc is currently in a long term uptrend where the price is trading 0.7% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Galectin Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 52.9% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 44.0% to $-5M since the same quarter in the previous year.
Based on the above factors, Galectin Therapeutics Inc gets an overall score of 2/5.